Disease · HP_0007185
Loss of consciousness
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. Loss of consciousness. Diseases, record HP_0007185. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0007185
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Loss of consciousness
- Open Targets ID
- HP_0007185
- Other names
- Fainting, Passing out
- Highest stage of its drugs
- Phase 3, for 1 of its 9 drugs, from ClinicalTrials.gov
Source Open Targets
Drugs9
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| REMIMAZOLAM | CHEMBL4297526 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| REMIMAZOLAM BESYLATE | CHEMBL4594301 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| PROPOFOL | CHEMBL526 | Small molecule | Phase 1 | ClinicalTrials.gov | 5 | 5 | 4 | Drugs and targets |
| REMIFENTANIL | CHEMBL1005 | Small molecule | Unknown | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| MIDAZOLAM | CHEMBL655 | Small molecule | Unknown | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| DEXMEDETOMIDINE | CHEMBL778 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ETOMIDATE | CHEMBL681 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| REMIMAZOLAM TOSYLATE | CHEMBL4297324 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| SUFENTANIL | CHEMBL658 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets20
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| GABRA1 | GABA-A receptor; anion channel | 5 | GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator | Phase 3 | https://conductscience.org/library/genes/2554 | Drugs and targets |
| GABRA2 | GABA-A receptor; anion channel | 5 | GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator | Phase 3 | https://conductscience.org/library/genes/2555 | Drugs and targets |
| GABRA3 | GABA-A receptor; anion channel | 5 | GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator | Phase 3 | https://conductscience.org/library/genes/2556 | Drugs and targets |
| GABRA4 | GABA-A receptor; anion channel | 5 | GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator | Phase 3 | https://conductscience.org/library/genes/2557 | Drugs and targets |
| GABRA5 | GABA-A receptor; anion channel | 5 | GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator | Phase 3 | https://conductscience.org/library/genes/2558 | Drugs and targets |
| GABRA6 | GABA-A receptor; anion channel | 5 | GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator | Phase 3 | https://conductscience.org/library/genes/2559 | Drugs and targets |
| GABRB1 | GABA-A receptor; anion channel | 5 | GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator | Phase 3 | https://conductscience.org/library/genes/2560 | Drugs and targets |
| GABRB2 | GABA-A receptor; anion channel | 5 | GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator | Phase 3 | https://conductscience.org/library/genes/2561 | Drugs and targets |
| GABRB3 | GABA-A receptor; anion channel | 5 | GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator | Phase 3 | https://conductscience.org/library/genes/2562 | Drugs and targets |
| GABRD | GABA-A receptor; anion channel | 5 | GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator | Phase 3 | https://conductscience.org/library/genes/2563 | Drugs and targets |
1 to 10 of 20
See all 20 targetsTrials10
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01543633 | EEG Studies of Induction and Recovery From Propofol Induced General Anesthesia | Not applicable | 36 | 2022-01-11 | Brain Activity Under Sedation | PROPOFOL | Its record names the disease | ClinicalTrials.gov |
| NCT02536690 | Remifentanil and Midazolam on Propofol for Loss of Consciousness | Not applicable | 120 | Anesthesia | MIDAZOLAM, PROPOFOL, REMIFENTANIL | Its record names the disease | ClinicalTrials.gov | |
| NCT02818387 | Remifentanil and Midazolam on Propofol for Loss of Consciousness in Elderly Patients | Not applicable | 120 | Anesthesia | MIDAZOLAM, PROPOFOL, REMIFENTANIL | Its record names the disease | ClinicalTrials.gov | |
| NCT04901871 | Remimazolam Bolus for General Anesthesia | Phase 3 | 120 | Loss of Consciousness | REMIMAZOLAM | Its record names the disease | ClinicalTrials.gov | |
| NCT05434494 | The Effect of Remifentanil on ED95 of Remimazolam for Loss of Consciousness in Adult Patients | Not applicable | 80 | Remimazolam | REMIFENTANIL, REMIMAZOLAM | Its record names the disease | ClinicalTrials.gov | |
| NCT02783846 | The Effects of Different Doses of Dexmedetomidine on Propofol Requirement for Loss of Consciousness Undergoing Bispectral Index: a Double-blinded, Placebo-controlled Trial | Not applicable | 73 | Loss of Consciousness | DEXMEDETOMIDINE, PROPOFOL | Its record names the disease | ClinicalTrials.gov | |
| NCT02831101 | Sufentanil Bispectral Index Elderly | Not applicable | 71 | Loss of Consciousness | SUFENTANIL | Its record names the disease | ClinicalTrials.gov | |
| NCT07467603 | ED50 of Remimazolam for Anesthesia Induction in Frail Elderly Patients | Not applicable | 58 | Frailty, Anesthesia Induction | REMIMAZOLAM TOSYLATE | Its record names the disease | ClinicalTrials.gov | |
| NCT03240055 | The Effects of Spinal Anesthesia on ED50 and BIS50 of Etomidate for the Loss of Consciousness | Not applicable | 54 | Dose-Response Relationship, Drug | ETOMIDATE | Its record names the disease | ClinicalTrials.gov | |
| NCT05975255 | Dose Finding Study for Remimazolam in Children | Phase 2 | 50 | Drug Effect | REMIMAZOLAM BESYLATE | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials0
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
None in this release.
Papers from its trials4
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0007185
GET https://conductscience.org/api/diseases/v1/HP_0007185/drugs